



Orano Appoints Rebecca Stewart as President of TN Americas

Financial experience in the nuclear packaging, nuclear fuel, and space research industries combines for unique strengths leading the business.

BETHESDA, Md., March 5, 2024 – We are pleased to announce that effective March 4, 2024, Rebecca Stewart has been appointed President of TN Americas (TNA), which is a subsidiary of Orano USA and part of the global Orano Nuclear Packages and Services (NPS) business unit.



Stewart joined Orano in 2020 as TNA’s Chief Financial Officer (CFO). Prior to that role, she held several finance positions, including Finance Manager at the Laboratory for Atmospheric Space Physics (LASP) at University of Colorado Boulder and CFO for Global Nuclear Fuel (a joint venture between GE & Hitachi). Early in her career, she held various roles with Sandia National Laboratories.

“We see many opportunities for TN Americas to explore and expand its market presence in the United States and globally,” said Frédéric de Agostini, President and CEO of Orano NPS. “As the new President of TN Americas, Rebecca brings the unique strengths needed to lead the business with this dynamic focus.”

“During her four years as CFO at TNA,” said Jean-Luc Palayer, CEO of Orano USA, “Rebecca’s financial insights and questioning attitude helped shift the business into a more competitive offering with a sharp focus on customer needs and market opportunities. I look forward to seeing her leadership further strengthen our TNA team and customer engagement.”

Stewart earned both a BBA in Accounting and an MBA in Accounting & International Management from the University of New Mexico, Albuquerque, NM.

About Orano USA: Orano USA, a regional subsidiary of Orano, is a leading supplier of advanced reactor services, nuclear fuel materials, used fuel management, decommissioning, decontamination, and radwaste treatment solutions to U.S. commercial and federal customers. Orano USA, through its subsidiary Orano Med in Texas, is also developing cancer treatments using targeted radio-immunotherapy in progress through FDA-authorized clinical trials.

###

Orano USA
4747 Bethesda Ave.
Suite 1001
Bethesda, Maryland 20814

Media Contact
Curtis Roberts
Press Officer
(202) 374-8766
curtis.roberts@orano.group